Shi S - Search Results

1

Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer.

Zhang P, Chen Z, Shi S, Li Z, Ye F, Song L, Zhang Y, Yin F, Zhang X, Xu J, Cheng Y, Su W, Shi M, Fan S, Tan P, Zhong C, Lu M, Shen L. Zhang P, et al. Among authors: shi s, shi m. Cancer Immunol Immunother. 2024 May 7;73(7):119. doi: 10.1007/s00262-024-03677-7. Cancer Immunol Immunother. 2024. PMID: 38713205 Free PMC article. Clinical Trial.

2

Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis.

Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, Ni Q, Shi S, Yu X. Zhang Y, et al. Among authors: shi s. J Cancer. 2019 Jul 23;10(18):4420-4429. doi: 10.7150/jca.29898. eCollection 2019. J Cancer. 2019. PMID: 31413762 Free PMC article.

3

Phase 1b study of first-line fuzuloparib combined with modified FOLFIRINOX followed by fuzuloparib maintenance monotherapy in pancreatic adenocarcinoma.

Wei M, Liu R, Xu Y, Chen X, Liu C, Bai X, Zhang X, Gao S, Li J, Sheng Z, Lian J, Wang W, Zhang J, Shi S, Xu J, Yu X. Wei M, et al. Among authors: shi s. BMC Med. 2024 Sep 4;22(1):365. doi: 10.1186/s12916-024-03581-y. BMC Med. 2024. PMID: 39232761 Free PMC article. Clinical Trial.

4

Combinational therapy: new hope for pancreatic cancer?

Shi S, Yao W, Xu J, Long J, Liu C, Yu X. Shi S, et al. Cancer Lett. 2012 Apr 28;317(2):127-35. doi: 10.1016/j.canlet.2011.11.029. Epub 2011 Dec 2. Cancer Lett. 2012. PMID: 22138436 Review.

5

Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Meng Q, Shi S, Liang C, Xiang J, Liang D, Zhang B, Qin Y, Ji S, Xu W, Xu J, Ni Q, Yu X. Meng Q, et al. Among authors: shi s. J Cancer. 2017 Oct 9;8(17):3615-3622. doi: 10.7150/jca.18901. eCollection 2017. J Cancer. 2017. PMID: 29151947 Free PMC article.

6

Proposed Modification of the 8th Edition of the AJCC Staging System for Pancreatic Ductal Adenocarcinoma.

Shi S, Hua J, Liang C, Meng Q, Liang D, Xu J, Ni Q, Yu X. Shi S, et al. Ann Surg. 2019 May;269(5):944-950. doi: 10.1097/SLA.0000000000002668. Ann Surg. 2019. PMID: 29334560

7

Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.

Liang D, Shi S, Liang C, Meng Q, Zhang B, Ni Q, Xu J, Yu X. Liang D, et al. Among authors: shi s. Surgery. 2018 May;163(5):1080-1089. doi: 10.1016/j.surg.2017.12.009. Epub 2018 Jan 17. Surgery. 2018. PMID: 29352574

8

A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.

Zhang Y, Xu J, Hua J, Liu J, Liang C, Meng Q, Wei M, Zhang B, Yu X, Shi S. Zhang Y, et al. Among authors: shi s. J Immunother Cancer. 2019 Aug 29;7(1):233. doi: 10.1186/s40425-019-0703-0. J Immunother Cancer. 2019. PMID: 31464648 Free PMC article.

9

PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.

Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. Zhu H, et al. Among authors: shi s. Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9. Mol Cancer. 2020. PMID: 32122376 Free PMC article. Review.

10

Comment on "Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic Adenocarcinoma".

Zhang YY, Xu J, Yu XJ, Shi S. Zhang YY, et al. Among authors: shi s. Ann Surg. 2021 Dec 1;274(6):e718. doi: 10.1097/SLA.0000000000003989. Ann Surg. 2021. PMID: 32482982 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,531 results

Search Page

Filters